Overview

A Randomized, Controlled Clinical Trial Meant to Evaluate the Use of Glibenclamide on Acute aSAH.

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
0
Participant gender:
All
Summary
A randomized, open-labeled, blank-controlled and prospective trial meant to evaluate the use of glibenclamide on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated randomly in two groups, one for 3.75 mg daily intake of glibenclamide for 7 days and another as a blank contrast. General clinical data and late cognitive status will be accessed in both groups.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborator:
Beijing Tongren Hospital
Treatments:
Glyburide
Criteria
Inclusion Criteria:

1. Subarachnoid hemorrhage was diagnosed by DSA, CTA or MRA;

2. Within 48 hours;

3. Age > 18 years old;

4. The expected length of stay is more than 7 days;

5. Sign informed consent.

Exclusion Criteria:

1. There was a history of taking sulfonylureas within 30 days before brain injury;

2. Combined with neurological or mental diseases, including stroke, epilepsy and
dementia;

3. Hunt & Hess grade V patients;

4. Severe brain injury (central hernia or hook hernia within 48 hours after admission or
after resuscitation) that cannot be solved at present;

5. History of alcohol or illicit drug dependence;

6. Allergic to sulfonamides or glibenclamide tablets;

7. The INR was more than 1.4;

8. Renal insufficiency, history of dialysis treatment or serum creatinine more than 2.5
mg / dl;

9. Liver cirrhosis or severe liver dysfunction (ALT > 2.5 times the upper normal limit or
total bilirubin > 1.5 times the upper normal limit);

10. He is taking bosentan tablets to treat pulmonary hypertension;

11. There was a history of G6PD deficiency (faba bean disease);

12. The life expectancy is less than one year;

13. The gastrointestinal tract should not be used;

14. Pregnancy or lactation;

15. History of participating in other drug trials within 30 days;

16. There were clinical conditions that other researchers did not consider to meet the
inclusion criteria.